p14ARF interacts with DAXX: Effects on HDM2 and p53

Cell Cycle

Volumn 7, Issue 12, 2008, Pages 1836-1850

  Ivanchuk, Stacey M ^a   Mondal, Soma ^a   Rutka, James T ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

DAXX; HDM2; Nucleolus; p14ARF; p53; Sumoylation; Ubiquitination

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DAXX PROTEIN; NUCLEOLIN; PROTEIN MDM2; PROTEIN P53; DAXX PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SUMO 1 PROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS INCLUSION BODY; CELL STRAIN; CELL STRAIN COS7; CONTROLLED STUDY; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SUMOYLATION; UBIQUITINATION; UPREGULATION; ANIMAL; BINDING SITE; CELL LINE; CELL NUCLEUS; CHEMISTRY; METABOLISM; NUCLEOLUS; TWO HYBRID SYSTEM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BINDING SITES; CELL LINE; CELL NUCLEOLUS; CELL NUCLEUS STRUCTURES; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; SUMO-1 PROTEIN; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TWO-HYBRID SYSTEM TECHNIQUES; UBIQUITINATION;

EID: 47249140412     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.12.6025     Document Type: Article

References (89)

1. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12:2984-91.
2. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.
3. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.
4. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998; 17:5001-14.
5. Tao W, Levine AJ. p19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 1999; 96:6937-41.
6. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1:20-6.
7. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19:2312-23.
8. ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001; 3:445-52.
9. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12:2424-33.
10. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA 2003; 100:15930-5.
11. ARF expression. Cell Cycle 2003; 2:127-33.
12. Parisi T, Pollice A, Di Cristofano A, Calabro V, La Mantia G. Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3 and Sp1-like factors. Biochem Biophys Res Commun 2002; 291:1138-45.
13. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 1997; 94:7245-50.
14. Kip1 without activating cyclin D-dependent kinases. J Biol Chem 2000; 275:27473-80.
15. Hasan MK, Yaguchi T, Minoda Y, Hirano T, Taira K, Wadhwa R, Kaul SC. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem J 2004; 380:605-10.
16. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071-83.
17. Pauklin S, Kristjuhan A, Maimets T, Jaks V. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem Biophys Res Commun 2005; 334:386-94.
18. Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41.
19. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24:985-96.
20. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12:1151-64.
21. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707.
22. ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7.
23. ARF) in activating p53. J Biol Chem 2002; 277:37765-70.
24. Kamrul HM, Wadhwa R, Kaul SC. CARF binds to three members (ARF, p53 and HDM2) of the p53 tumor-suppressor pathway. Ann N Y Acad Sci 2007; 1100:312-5.
25. Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J Biol Chem 2007; 282:1322-33.
26. Wang J, He X, Luo Y, Yarbrough WG. A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochem J 2006; 393:489-501.
27. Tompkins V, Hagen J, Zediak VP, Quelle DE. Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle 2006; 5:641-6.
28. Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, Seite P. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 2006; 25:7577-86.
29. Ayrault O, Andrique L, Larsen CJ, Seite P. Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 2004; 23:8097-104.
30. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24.
31. ARF tumor suppressor with ribosomes. J Biol Chem 2006; 281:38080-8.
32. Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999; 3:579-91.
33. ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes. Mol Cancer 2003; 2:18.
34. Lindstrom MS, Klangby U, Inoue R, Pisa P, Wiman KG, Asker CE. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 2000; 256:400-10.
35. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, Quelle DE. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25:1258-71.
36. Arf promotes SUMO conjugation of Werners helicase. J Biol Chem 2004; 279:50158-66.
37. Tago K, Chiocca S, Sherr CJ. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc Natl Acad Sci USA 2005; 102:7689-94.
38. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
39. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002; 22:196-206.
40. Gallagher SJ, Kefford RF, Rizos H. The ARF tumour suppressor. Int J Biochem Cell Biol 2006; 38:1637-41.
41. Chen L, Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003; 22:5348-57.
42. ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism. Cell Cycle 2007; 6:1741-7.
43. ARF-expressing cells. Int J Cancer 2003; 105:644-53.
44. Michaelson JS. The Daxx enigma. Apoptosis 2000; 5:217-20.
45. Kim EJ, Park JS, Um SJ. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML. Nucleic Acids Res 2003; 31:5356-67.
46. Zhao LY, Colosimo AL, Liu Y, Wan Y, Liao D. Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates enhancement of p53-dependent transcription by Daxx. J Virol 2003; 77:11809-21.
47. Zhao LY, Liu J, Sidhu GS, Niu Y, Liu Y, Wang F, Liao D. Negative regulation of p53 functions by daxx and the involvement of MDM2. J Biol Chem 2004; 279:50566-79.
48. Michaelson JS, Leder P. RNAi reveals anti-apoptotic and transcriptionally repressive activities of DAXX. J Cell Sci 2003; 116:345-52.
49. Mason SL, Loughran O, La Thangue NB. p14(ARF) regulates E2F activity. Oncogene 2002; 21:4220-30.
50. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408.
51. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NFkappaB transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25.
52. Gostissa M, Morelli M, Mantovani F, Guida E, Piazza S, Collavin L, Brancolin C, Scheneider C, Del Sal G. The transcriptional repressor hDAXX potentiates p53-dependent apoptosis. J Biol Chem 2004; 279:48013-23.
53. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006; 8:855-62.
54. Jang MS, Ryu SW, Kim E. Modification of Daxx by small ubiquitin-related modifier-1. Biochem Biophys Res Commun 2002; 295:495-500.
55. ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276:28421-9.
56. Karayan L, Riou JF, Seite P, Migeon J, Cantereau A, Larsen CJ. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001; 20:836-48.
57. Lin DY, Shih HM. Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration. J Biol Chem 2002; 277:25446-56.
58. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95.
59. ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002; 528:207-11.
60. ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001; 20:4972-83.
61. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986; 234:364-8.
62. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996; 21:267-71.
63. Nakagawa K, Yokosawa H. PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1. FEBS Lett 2002; 530:204-8.
64. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND, Hay RT. P300 transcriptional repression is mediated by SUMO modification. Mol Cell 2003; 11:1043-54.
65. Yang SH, Jaffray E, Senthinathan B, Hay RT, Sharrocks AD. SUMO and transcriptional repression: dynamic interactions between the MAP kinase and SUMO pathways. Cell Cycle 2003; 2:528-30.
66. Wood LD, Irvin BJ, Nucifora G, Luce KS, Hiebert SW. Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci USA 2003; 100:3257-62.
67. Long J, Wang G, He D, Liu F. Repression of Smad4 transcriptional activity by SUMO modification. Biochem J 2004; 379:23-9.
68. Chen WY, Lee WC, Hsu NC, Huang F, Chung BC. SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1). J Biol Chem 2004; 279:38730-5.
69. Yang SH, Sharrocks AD. SUMO promotes HDAC-mediated transcriptional repression. Mol Cell 2004; 13:611-7.
70. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC. p53 induces NFkappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 2004; 279:26115-25.
71. Kristjuhan A, Maimets T. Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner. Eur J Biochem 1995; 234:827-31.
72. WAF1/CIP1 promoter. Oncogene 1999; 18:263-8.
73. Schuster N, Prowald A, Schneider E, Scheidtmann KH, Montenarh M. Regulation of p53 mediated transactivation by the beta-subunit of protein kinase CK2. FEBS Lett 1999; 447:160-6.
74. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. Embo J 1999; 18:6455-61.
75. Melchior F, Hengst L. SUMO-1 and p53. Cell Cycle 2002; 1:245-9.
76. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 2000; 275:13321-9.
77. Torii S, Egan DA, Evans RA, Reed JC. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). Embo J 1999; 18:6037-49.
78. Liu X, Liu Z, Jang SW, Ma Z, Shinmura K, Kang S, Dong S, Chen J, Fukasawa K, Ye K. Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci USA 2007; 104:9679-84.
79. Girdwood DW, Tatham MH, Hay RT. SUMO and transcriptional regulation. Semin Cell Dev Biol 2004; 15:201-10.
80. Muller S, Ledl A, Schmidt D. SUMO: a regulator of gene expression and genome integrity. Oncogene 2004; 23:1998-2008.
81. ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 2005; 4:597-603.
82. Ghosh M, Weghorst K, Berberich SJ. MdmX inhibits ARF mediated Mdm2 sumoylation. Cell Cycle 2005; 4:604-8.
83. Lee MH, Lee SW, Lee EJ, Choi SJ, Chung SS, Lee JI, Cho JM, Seol JH, Baek SH, Kim KI, Chiba T, Tanaka K, Bang OS, Chung CH. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol 2006; 8:1424-31.
84. ARF mediated inhibition of MDM2. Oncogene 2002; 21:4498-507.
85. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. Embo J 1999; 18:22-7.
86. Kwek SS, Derry J, Tyner AL, Shen Z, Gudkov AV. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 2001; 20:2587-99.
87. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. Embo J 1999; 18:6462-71.
88. Chang CC, Lin DY, Fang HI, Chen RH, Shih HM. Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4. J Biol Chem 2005; 280:10164-73.
89. Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, Borrelli L, Saviozzi S, La Mantia G. The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem 2001; 276:14161-9.